With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise.
The biotech sector, as measured by the XBI ETF, fell more than 2% in Tuesday's session, pressured by a combination of macroeconomic headwinds and negative company-specific news. A hotter-than-expected inflation report sparked fears of more aggressive interest rate hikes from the Federal Reserve, creating a risk-off sentiment that disproportionately affects growth sectors like biotechnology. [18] This broad market pressure was intensified by significant declines in component stocks. Legend Biotech (LEGN) shares fell sharply after the company reported a surprise quarterly loss, raising concerns about its profitability. [5] Additionally, Moderna (MRNA) stock traded lower amid skepticism over its vaccine franchise's commercial prospects. [9]